查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1417484

血液腫瘤檢測市場報告：至2030年的趨勢、預測與競爭分析

Hemato Oncology Testing Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

血液腫瘤檢測的趨勢和預測

到2030年，全球血液腫瘤檢測市場預計將達到 72 億美元，2024年至2030年年複合成長率為 14.5%。市場的主要驅動力是個人化醫療學術團體數量的增加、血癌盛行率的上升以及私人診斷設施數量的增加。全球血液腫瘤檢測市場的未來充滿希望，醫院和學術/研究機構市場充滿機會。

血液腫瘤檢測市場洞察

Lucintel 預測，由於大眾對各種治療方案（包括定製藥物療法）的了解不斷增加，服務在預測期內將繼續佔據更大的佔有率。

由於多發性骨髓瘤、淋巴瘤和白血病的盛行率不斷上升，擁有最先進的醫療設施和醫療保健，以及新技術的引進，北美在預測期內可能仍然是最大的地區。

常問問題

Q1.市場規模有多大？

A1.到2030年，全球血液腫瘤檢測市場預計將達到 72 億美元。

Q2.市場成長預測如何？

A2.2024年至2030年，全球血液腫瘤檢測市場預計將以14.5%的年複合成長率成長。

Q3.影響市場成長的主要促進因素有哪些？

A3.該市場的主要驅動力是個人化醫療學術會議數量的增加、血癌發病率的上升以及私人診斷設施數量的增加。

Q4.市場的主要細分市場是什麼？

A4.全球血液腫瘤檢測市場前景廣闊，醫院、學術和研究機構市場充滿機會。

Q5.市場上主要企業有哪些？

A5.主要血液腫瘤檢測公司如下。

  • F. Hoffmann-La Roche
  • Abbott
  • EntroGen
  • Qiagen
  • Cepheid
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Illumina
  • Amoy Diagnostics
  • ArcherDX

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預計，由於大眾對各種治療方案（包括定製藥物療法）的了解不斷增加，服務在預測期內仍將佔據更大的佔有率。

Q7.未來五年預計哪個地區將成為最大的市場？

A7.由於多發性骨髓瘤、淋巴瘤和白血病盛行率不斷上升，擁有最先進的醫療設施和醫療保健，以及新技術的引進，在預測期內，北美將繼續成為最大的地區。

Q8.可以客製化報告嗎？

A8.是的，Lucintel 提供 10%的客製化服務，無需額外付費。

目錄

第1章 執行摘要

第2章 全球血液腫瘤檢測市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球血液腫瘤檢測市場趨勢（2018-2023）與預測（2024-2030）
  • 依技術分類的全球血液腫瘤檢測市場
    • PCR
    • IHC
    • NGS
    • 細胞遺傳學
    • 其他
  • 按癌症類型分類的全球血液腫瘤檢測市場
    • 白血病
    • 淋巴瘤
    • 骨髓增生性腫瘤
    • 其他
  • 依產品分類的全球血液腫瘤檢測市場
    • 檢測套件和試劑
    • 服務
  • 依最終用途分類的全球血液腫瘤學測試市場
    • 醫院
    • 學術研究所
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球血液腫瘤檢測市場（依地區）
  • 北美血液腫瘤檢測市場
  • 歐洲血液腫瘤檢測市場
  • 亞太地區血液腫瘤檢測市場
  • 其他地區血液腫瘤檢測市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按技術分類的全球血液腫瘤檢測市場成長機會
    • 按癌症類型分類的全球血液腫瘤學測試市場成長機會
    • 依產品分類的全球血液腫瘤檢測市場成長機會
    • 依最終用途分類的全球血液腫瘤學測試市場成長機會
    • 依地區分類的全球血液腫瘤檢測市場成長機會
  • 全球血液腫瘤檢測市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 全球血液腫瘤檢測市場的產能擴張
    • 全球血液腫瘤檢測市場的合併、收購與合資
    • 認證和許可

第7章 主要企業概況

  • F. Hoffmann-La Roche
  • Abbott
  • EntroGen
  • Qiagen
  • Cepheid
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Illumina
  • Amoy Diagnostics
  • ArcherDX
簡介目錄

Hemato Oncology Testing Trends and Forecast

The future of the global hemato oncology testing market looks promising with opportunities in the hospital and academic & research institutes market. The global hemato oncology testing market is expected to reach an estimated $7.2 billion by 2030 with a CAGR of 14.5% from 2024 to 2030. The major drivers for this market are increasing the number of conferences on personalized medicine, rising rate of hematologic cancer, and growing number of privately run diagnostic facilities.

A more than 150-page report is developed to help in your business decisions.

Hemato Oncology Testing by Segment

The study includes a forecast for the global hemato oncology testing by technology, cancer type, product, end use, and region.

Hemato Oncology Testing Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

  • PCR
  • IHC
  • NGS
  • Cytogenetics
  • Others

Hemato Oncology Testing Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

  • Leukemia
  • Lymphoma
  • Myeloproliferative Neoplasms
  • Other

Hemato Oncology Testing Market by Product [Shipment Analysis by Value from 2018 to 2030]:

  • Assay Kits and Reagents
  • Services

Hemato Oncology Testing Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Academic & Research Institutes
  • Others

Hemato Oncology Testing Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Hemato Oncology Testing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies hemato oncology testing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the hemato oncology testing companies profiled in this report include-

  • F. Hoffmann-La Roche
  • Abbott
  • EntroGen
  • Qiagen
  • Cepheid
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Illumina
  • Amoy Diagnostics
  • ArcherDX

Hemato Oncology Testing Market Insights

Lucintel forecasts that service will remain the larger segment over the forecast period due to increasing public knowledge of various treatment options, including tailored medications.

North America will remain the largest region over the forecast period due to the increased prevalence of multiple myeloma, lymphoma, and leukemia, along with the availability of cutting-edge medical facilities and healthcare, as well as the introduction of new technology.

Features of the Global Hemato Oncology Testing Market

Market Size Estimates: Hemato oncology testing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Hemato oncology testing market size by various segments, such as by technology, cancer type, product, end use, and region in terms of value ($B).

Regional Analysis: Hemato oncology testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different technology, cancer type, product, end use, and regions for the hemato oncology testing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the hemato oncology testing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the hemato oncology testing market size?

Answer: The global hemato oncology testing market is expected to reach an estimated $7.2 billion by 2030.

Q2. What is the growth forecast for hemato oncology testing market?

Answer: The global hemato oncology testing market is expected to grow with a CAGR of 14.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the hemato oncology testing market?

Answer: The major drivers for this market are increasing the number of conferences on personalized medicine, rising rate of hematologic cancer, and growing number of privately run diagnostic facilities.

Q4. What are the major segments for hemato oncology testing market?

Answer: The future of the global hemato oncology testing market looks promising with opportunities in the hospital and academic & research institutes market.

Q5. Who are the key hemato oncology testing market companies?

Answer: Some of the key hemato oncology testing companies are as follows.

  • F. Hoffmann-La Roche
  • Abbott
  • EntroGen
  • Qiagen
  • Cepheid
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Illumina
  • Amoy Diagnostics
  • ArcherDX

Q6. Which hemato oncology testing market segment will be the largest in future?

Answer: Lucintel forecasts that service will remain the larger segment over the forecast period due to increasing public knowledge of various treatment options, including tailored medications.

Q7. In hemato oncology testing market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to the increased prevalence of multiple myeloma, lymphoma, and leukemia, along with the availability of cutting-edge medical facilities and healthcare, as well as the introduction of new technology.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the hemato oncology testing market by technology (PCR, IHC, NGS, cytogenetics, and others), cancer type (leukemia, lymphoma, myeloproliferative neoplasms, and other), product (assay kits and reagents and services), end use (hospitals, academic & research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Hemato Oncology Testing Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Hemato Oncology Testing Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Hemato Oncology Testing Market by Technology
    • 3.3.1: PCR
    • 3.3.2: IHC
    • 3.3.3: NGS
    • 3.3.4: Cytogenetics
    • 3.3.5: Others
  • 3.4: Global Hemato Oncology Testing Market by Cancer Type
    • 3.4.1: Leukemia
    • 3.4.2: Lymphoma
    • 3.4.3: Myeloproliferative Neoplasms
    • 3.4.4: Other
  • 3.5: Global Hemato Oncology Testing Market by Product
    • 3.5.1: Assay Kits and Reagents
    • 3.5.2: Services
  • 3.6: Global Hemato Oncology Testing Market by End Use
    • 3.6.1: Hospitals
    • 3.6.2: Academic & Research Institutes
    • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Hemato Oncology Testing Market by Region
  • 4.2: North American Hemato Oncology Testing Market
    • 4.2.1: North American Hemato Oncology Testing Market by Product: Assay Kits and Reagents and Services
    • 4.2.2: North American Hemato Oncology Testing Market by End Use: Hospitals, Academic & Research Institutes, and Others
  • 4.3: European Hemato Oncology Testing Market
    • 4.3.1: European Hemato Oncology Testing Market by Product: Assay Kits and Reagents and Services
    • 4.3.2: European Hemato Oncology Testing Market by End Use: Hospitals, Academic & Research Institutes, and Others
  • 4.4: APAC Hemato Oncology Testing Market
    • 4.4.1: APAC Hemato Oncology Testing Market by Product: Assay Kits and Reagents and Services
    • 4.4.2: APAC Hemato Oncology Testing Market by End Use: Hospitals, Academic & Research Institutes, and Others
  • 4.5: ROW Hemato Oncology Testing Market
    • 4.5.1: ROW Hemato Oncology Testing Market by Product: Assay Kits and Reagents and Services
    • 4.5.2: ROW Hemato Oncology Testing Market by End Use: Hospitals, Academic & Research Institutes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Hemato Oncology Testing Market by Technology
    • 6.1.2: Growth Opportunities for the Global Hemato Oncology Testing Market by Cancer Type
    • 6.1.3: Growth Opportunities for the Global Hemato Oncology Testing Market by Product
    • 6.1.4: Growth Opportunities for the Global Hemato Oncology Testing Market by End Use
    • 6.1.5: Growth Opportunities for the Global Hemato Oncology Testing Market by Region
  • 6.2: Emerging Trends in the Global Hemato Oncology Testing Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Hemato Oncology Testing Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Hemato Oncology Testing Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: F. Hoffmann-La Roche
  • 7.2: Abbott
  • 7.3: EntroGen
  • 7.4: Qiagen
  • 7.5: Cepheid
  • 7.6: Thermo Fisher Scientific
  • 7.7: Bio-Rad Laboratories
  • 7.8: Illumina
  • 7.9: Amoy Diagnostics
  • 7.10: ArcherDX